CTN New England Consortium Node

In this Administrative Supplement, the New England Consortium Node (NECN), led by Gail D’Onofrio MD, of Yale University, and Roger Weiss, MD, of McLean Hospital, is requesting support for approved, ongoing CTN studies including: CTN-0100 (RDD) Optimizing Retention, Duration, Discontinuation Strategies for OUD Roger Weiss, MD, McLean Hospital, Co-Lead Investigator with Drs. John Rotrosen & Edward Nunes, Greater NY Node CTN-0126 Following Outcomes Remotely Within Addiction Recovery Domains R. Kathryn McHugh, PhD, McLean Hospital NECN, Co-Lead Investigator with Rebecca Ottesen (EMMES Company LLC) and Matisyahu Shulman, MD from the New York Node CTN-0131 Office-based Methadone vs Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment: A Randomized Pragmatic Hybrid Among Patients Not Optimally Benefitting From Office- based BUP – a hybrid Effectiveness/Implementation Trial David Fiellin, Lead Investigator, NECN CTN-0145 Standard versus High Dose ED-Initiated Buprenorphine Induction Kathryn Hawk, MD, Gail D’Onofrio, MD Co-Lead Investigators, NECN Andrew Herring, MD, Co-Lead Investigator CTN-0146 Adolescent outcomes of Post-operative opioid Exposure (APEX) Sharon Levy, MD and Joseph Cravero, MD, Co-Lead Investigators, NECN CTN-0154 EMS initiated Buprenorphine for Opioid Use Disorder Gerard Carroll, MD, Andrew Herring, MD, Nicholas Simpson, MD, Gail D’Onofrio, MD, (NECN) Co-Lead Investigators The NECN has an ideal combination of cutting-edge investigators, superb research-friendly clinical sites, and outstanding productivity. We have the scientific expertise and clinical research infrastructure to lead, participate in, and complete these projects.